B7-33 (Relaxin-3 Receptor Agonist) Peptide

A landmark study by Kuei et al. (2007) in the Journal of Biological Chemistry comprehensively characterized the pharmacological properties of B7-33 and established its utility as a selective RXFP3 research tool. The investigators systematically evaluated the binding affinity and functional activity of various relaxin-3 fragments across different relaxin family receptors using both radioligand binding assays and functional cAMP measurements. B7-33 demonstrated remarkable selectivity, exhibiting an EC₅₀ of approximately 2.1 nM for RXFP3 activation while showing no detectable activity at RXFP1 receptors up to concentrations of 10 μM. The study employed multiple complementary approaches to validate B7-33's selectivity profile, including competition binding studies using radiolabeled relaxin-3 and functional assays measuring cAMP accumulation in cells expressing different relaxin receptors. Importantly, the researchers demonstrated that B7-33 retained full agonist activity at RXFP3 receptors, achieving maximal responses comparable to full-length relaxin-3 but with improved selectivity. The peptide's stability and pharmacokinetic properties were also evaluated, showing superior resistance to proteolytic degradation compared to the full-length hormone. Further characterization revealed that B7-33's selectivity stems from specific structural features within the peptide sequence that are recognized by RXFP3 but not RXFP1 receptors. Mutation studies identified critical amino acid residues essential for RXFP3 binding and activation, providing insights into the molecular basis of receptor selectivity. These findings established B7-33 as the gold standard selective RXFP3 agonist for research applications, enabling more precise investigation of RXFP3-mediated physiological processes without the confounding effects of RXFP1 activation. The research also demonstrated B7-33's utility in tissue distribution studies, revealing widespread RXFP3 expression in brain regions involved in stress response, feeding behavior, and autonomic regulation. This comprehensive characterization has made B7-33 an essential tool for the relaxin research community and has facilitated numerous subsequent studies investigating RXFP3 biology.

Smith et al. (2011) conducted a pivotal study published in Neuropsychopharmacology investigating B7-33's effects on stress-related behaviors and feeding regulation using rodent models. The research team administered B7-33 via intracerebroventricular injection to examine its role in modulating hypothalamic-pituitary-adrenal (HPA) axis activity and feeding behavior. Results demonstrated that B7-33 treatment significantly increased food intake in fasted animals, with a dose-dependent effect observed at concentrations ranging from 0.1 to 3.0 nmol. The peptide's orexigenic effects were blocked by prior administration of RXFP3 antagonists, confirming receptor-mediated mechanisms. The study also revealed B7-33's potent anxiogenic properties, with treated animals showing increased anxiety-like behaviors in elevated plus maze and open field tests. Plasma corticosterone measurements indicated that B7-33 administration led to sustained elevation of stress hormones, suggesting activation of central stress response pathways through RXFP3 receptors. Importantly, these effects were anatomically specific, with microinjection studies showing that B7-33 was most effective when administered to the paraventricular nucleus of the hypothalamus and central nucleus of the amygdala, brain regions rich in RXFP3 receptors. Neurochemical analysis revealed that B7-33 treatment altered neurotransmitter release patterns in key brain regions, including increased norepinephrine release in the hypothalamus and enhanced GABA signaling in amygdalar circuits. These changes correlated with the observed behavioral effects and provided mechanistic insights into how RXFP3 activation influences stress and feeding systems. The study also demonstrated that chronic B7-33 administration led to adaptive changes in receptor expression and downstream signaling pathways, highlighting the dynamic nature of RXFP3 systems. This research established B7-33 as a valuable tool for investigating the neural circuits underlying stress-feeding interactions and has informed subsequent studies on the therapeutic potential of targeting RXFP3 receptors for metabolic and psychiatric disorders. The findings have been particularly influential in understanding how relaxin-3/RXFP3 signaling contributes to stress-induced feeding behaviors and the development of anxiety-related disorders.